Zang, Richard

Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research

Tuntland, T., Ethell, B., Kosaka, T., Blasco, F., Zang, R. X., Jain, M., Gould, T., & Hoffmaster, K. (2014) · Frontiers in Pharmacology

Statistical Methods in Clinical TrialsPharmaceutical studies and practices

Cited by 239

Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity

Pillow, T. H., Adhikari, P., Blake, R. A., Chen, J., Del Rosario, G., Deshmukh, G., Figueroa, I., Gascoigne, K. E., Kamath, A. V., Kaufman, S., et al. (2020) · ChemMedChem

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 216

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

Hagenbeek, T. J., Zbieg, J. R., Hafner, M., Mroue, R., Lacap, J. A., Sodir, N. M., Noland, C. L., Afghani, S., Kishore, A., Bhat, K. P., et al. (2023) · Nature Cancer

Hippo pathway signaling and YAP/TAZMicrotubule and mitosis dynamics

Cited by 215

Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)

Dragovich, P. S., Adhikari, P., Blake, R. A., Blaquiere, N., Chen, J., Cheng, Y.-X., den Besten, W., Han, J., Hartman, S. J., He, J., et al. (2020) · Bioorganic & Medicinal Chemistry Letters

Protein Degradation and InhibitorsMonoclonal and Polyclonal Antibodies Research

Cited by 120

Developments in MLflow: A System to Accelerate the Machine Learning Lifecycle

Chen, A., Chow, A., Davidson, A., DCunha, A., Ghodsi, A., Hong, S. A., Konwinski, A., Mewald, C., Murching, S., Nykodym, T., et al. (2020) · Proceedings of the Fourth International Workshop on Data Management for End-to-End Machine Learning

Scientific Computing and Data ManagementMachine Learning and Data Classification

Cited by 112